Shows
BSPE Legal Marketing PodcastWhat is MCL 257.321 – Surrender of License; Replacement in Michigan? - Paul J. TafelskiFrom Paul J. Tafelski, Michigan Defense Law – What is MCL 257.321 – Surrender of License; Replacement in Michigan? explores the critical legal framework governing driver’s license suspensions and revocations across the state. This episode discusses how MCL 257.321 requires Michigan drivers to surrender their licenses when facing a suspension or revocation, and outlines the administrative process for obtaining a replacement once the suspension period ends. The conversation delves into the real-life impacts these legal challenges have on employment, mobility, and daily responsibilities.The episode highlights the key provisions of MCL 257.321, which mandates individuals to promptly surrender their physical license to the...
2026-01-1505 min
BSPE Legal Marketing PodcastMCL 257.320 – Duration of Revocation or Suspension; Eligibility for Reinstatement - Paul J. TafelskiFrom Paul J. Tafelski, Michigan Defense Law – MCL 257.320 – Duration of Revocation or Suspension; Eligibility for Reinstatement explores how Michigan drivers can navigate the challenges of license suspension or revocation and what steps are required for reinstatement. This podcast dives into the complexities of MCL 257.320 – Duration of Revocation or Suspension; Eligibility for Reinstatement, a law that outlines the duration of license revocations or suspensions, eligibility requirements for reinstatement, and the importance of legal support in restoring your driving privileges.Listeners will learn how the Michigan Secretary of State enforces license actions under MCL 257.320 and related statutes like MCL 257.320a, 257...
2026-01-1505 min
BSPE Legal Marketing PodcastWhat is MCL 257.304 in Michigan: Issuance of License or Permit After Revocation/Suspension? - Paul J. TafelskiFrom Paul J. Tafelski, Michigan Defense Law – What is MCL 257.304 in Michigan: Issuance of License or Permit After Revocation/Suspension breaks down the complex process of regaining driving privileges after a license revocation or suspension. This episode explores how MCL 257.304 serves as a legal pathway for individuals with multiple OWI convictions or serious traffic offenses to obtain a restricted license. With insights into specialty court programs, ignition interlock requirements, and the role of the Michigan Secretary of State, listeners will gain a deeper understanding of what it takes to get back on the road legally in Michigan.Fo...
2025-12-1706 min
BSPE Legal Marketing PodcastWhat is MCL 257.303 in Michigan: Denial, Suspension, or Revocation of License? - Paul J. TafelskiFrom Michigan Defense Law – MCL 257.303 in Michigan: Denial, Suspension, or Revocation of License explores how Michigan’s traffic statute impacts drivers facing the denial, suspension, or revocation of their license. This episode unpacks the legal foundations of MCL 257.303 and highlights the real-world implications for drivers across the state. Whether dealing with habitual offender classifications or administrative hearing procedures, listeners will gain a clearer understanding of what triggers license actions and how to respond effectively.We’ll dive into the key provisions of MCL 257.303, including scenarios that lead to licensing prohibitions such as unresolved court violations, failed medical or kno...
2025-12-1505 min
PT Snacks Podcast: Physical Therapy with Dr. Kasey Hankins147. MCL Injuries: Anatomy, Causes, and TreatmentsSend a textIn this episode of the PT Snacks podcast, host Kasey delves into medial collateral ligament (MCL) injuries. Listeners will gain insights into the anatomy of the MCL, common causes of injury, and who is most susceptible. The episode also covers how to assess and diagnose MCL injuries using specific tests and medical imaging, as well as treatment options and prognosis for different injury grades. Suitable for physical therapists and students, this episode provides essential knowledge to enhance their understanding of knee injuries and effective treatment strategies.00:00 Introduction to MCL Injuries01:55...
2025-09-0910 min
The New Grad Physio PodcastMCL Knee Bracing & RehabRehab for MCL (medial collateral ligament) knee injuries can (and should) start from Day 0!Yet most therapists don't do this...And it makes no sense why!Even in a brace, and even when the brace is locked, preventing any knee movement...There is so much you can do!Listen to this week's podcast episode to discover...My exact MCL (and LCL) bracing protocol (and why it is much shorter than most!)Early, Mid-Stage & End-Stage MCL Rehab Examples The Missing Link In MCL Rehab - Causing The Most Common...
2025-09-0431 minThe New Grad Physio PodcastMCL Knee Injuries - Part 2In part 2 of this MCL mini-series we cover knee medial collateral ligament (MCL) injuries and specifically...- MCL Special Testing (inc. The 2 MCL Tests You Need To Know)- Ordering & Executing The Right Knee Special Tests- MCL (And LCL) BracingEnjoy the show!Andy BarkerThe New Grad Physio MentorPS. Keep your eyes peeled for part 3, where we will cover high grade MCL injury rehab...Including a case study, which will show you how to take a MCL injury from the...
2025-08-2823 min
The Fitness Pain Free ShowWhat Physical Therapists NEED to Know About MCL Injuries📌 FREE Guide - MCL Injury Evidence Based Exercise "Cheat Sheet" https://fitnesspainfree.com/programs/mcl-injury-cheat-sheet-lead-magnet/ Thanks for watching!👉 Check out the FPF Mini Course with "7 Reasons Why People Get Hurt in the Gym and What to do About It." https://fitnesspainfree.com/programs/fpf-certification-presale-page/ 👉 Rotator Cuff MASTER Course (Insiders) - https://fitnesspainfree.com/programs/fpf-insiders/ Show Notes:- https://fitnesspainfree.com/2025/03/what-physical-therapists-need-to-know-about-mcl-injuries/In today's episode we go over What Physical Therapists NEED to Know About MCL Injuries - FPF Show Episode 1640:00 Introduction1:32 How common are MCL injuries? (prevalence...
2025-03-1557 min
The Optimal Body368 | MCL Strain Around the Knee? What You Need To KnowIn this episode of the Optimal Body Podcast, hosts Doc Jen and Doctor Dom, both doctors of physical therapy, discuss MCL (medial collateral ligament) strains. They explain the anatomy and function of the MCL, common injury mechanisms, and the grading of MCL injuries. Emphasizing the importance of foot health and mobility for knee stability, they outline the rehabilitation process, highlighting the role of physical therapy in recovery. The episode underscores the significance of proper rehabilitation to regain strength and stability, offering valuable insights for women looking to understand and manage MCL injuries effectively.
FREE plan + a chance...
2024-08-0524 min
ReachMD CMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCLCME credits: 0.50
Valid until: 23-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment...
2024-07-2300 minReachMD CMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCLCME credits: 0.50
Valid until: 23-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment...
2024-07-2300 min
Ortho Eval Pal: Optimizing Orthopedic Evaluations and Management SkillsEvaluating and Treating MCL Injuries | OEP340Send us a textToday, I talk about Evaluating and Treating MCL Injuries.I discuss...-Anatomy of the MCL-Evaluating the MCL and special tests-Surrounding structures that can be affected when the MCL is injured.-Treatment recommendations and so much more!!(Video) MCL Evaluation(Video) Positive Brush Test(Video) ACL EvaluationMeet our new sponsor: Tread Labs!!👉I've been...
2024-05-2816 minThe New Grad Physio PodcastMCL Knee Acute Injury ManagementUnless you have seen loads of medial collateral ligament (MCL) injuries previously it is likely you might not know the best way to manage this type of injury...
Especially given the lack of teaching you were given around these types of problems at University!
So here is some help!
In this episode you will discover some of the key considerations around early MCL injury management including...
- Bracing protocols
- The best types of braces to use
- The clinical reasoning for bracing all grades of MCL...
2024-05-0221 min
TALKS4LIFEJak SKUTECZNIE leczyć uszkodzenie więzadła pobocznego piszczelowego (MCL)?Uszkodzenie więzadła pobocznego piszczelowego to jedna z częstszych kontuzji, do których dochodzi u osób aktywnych fizycznie. Narty i sporty kontaktowe to typowe okoliczności dla tego urazu, ale jeżeli myślisz, że osoby nieuprawiające sportu nie doświadczają tego typu kontuzji... musimy Cię rozczarować. Codzienne sytuacje, niefortunne popchnięcie i śliska nawierzchnia również mogą doprowadzić do tego typu urazu. Jeżeli zastanawiasz się:jakie są objawy uszkodzonego więzadła pobocznego piszczelowego?jak wygląda rehabilitacja uszkodzonego MCL?czy po uszkodzeniu MCL zalecane są kule lub orteza?czy uszkodzenie MCL leczy się operacyjnie?c...
2024-02-2136 min
Cut and RunS4 EP1 MCL Injuries. What is it and how is it injured?A discussion on MCL injuries. Learn everything you need to know about the MCL @cutandrunpodcast Season 4 Episode 1
What is the MCL? What is the function of the MCL?How is the MCL injured?What does it feel like to injure your ACL?Does it have the ability to heal?
Thanks for listening If you have any questions then send us an email at cutandrunpodcast@gmail.com to let us know if you have any topics you would like us to cover. See you next time.
2024-02-0506 min
Where East Meets West with Dr. David CherianMCL Tears and Sports InjuriesMCL Tears, Sports Injuries and Xu Duan
The medial collateral ligament (MCL) runs on the inside of the knee, responsible for connecting the tibial and femur. It provides lateral stability when the knee joint is in motion, so when MCL injuries occur, it can compromise the knee’s ability to function.
MCL injuries are common in contact sports, where any impact that drives the knee inward can result in a strain or tear. Depending on the injury’s severity, an MCL tear can sideline an athlete or anyone else for months befor...
2024-01-0807 min
Where East Meets West with Dr. David CherianMCL Tears and Sports InjuriesMCL Tears, Sports Injuries and Xu Duan
The medial collateral ligament (MCL) runs on the inside of the knee, responsible for connecting the tibial and femur. It provides lateral stability when the knee joint is in motion, so when MCL injuries occur, it can compromise the knee’s ability to function.
MCL injuries are common in contact sports, where any impact that drives the knee inward can result in a strain or tear. Depending on the injury’s severity, an MCL tear can sideline an athlete or anyone else for months befor...
2024-01-0807 min
The Sports Docs Podcast62. Dr. Brett Owens: MCL Injuries - Part IIWe return today with Dr. Brett Owens to shift our discussion of MCL tears on to the treatment of isolated and combined MCL injuries, then wrap up with a discussion on safe return to play.Our conversation picks back up with a level 1 prospective multicenter RCT from the March 2022 issue of AJSM titled “Comparative Outcomes Occur After Superficial Medial Collateral Ligament Augmented Repair vs. Reconstruction.” Fifty-four patients with grade III MCL injuries were randomized to either MCL augmented repair or MCL reconstruction using a free semitendinosus autograft. At 1-year post-op, there was no difference in objective outcomes (incl...
2023-12-1142 minThe Sports Docs Podcast61. Dr. Brett Owens: MCL Injuries - Part IOn today’s episode we’re focusing on medial collateral ligament injuries with Dr. Brett Owens. We’ll start off our discussion today with an article authored by our guest, Dr. Brett Owens, titled “The Epidemiology of Medial Collateral Ligament Sprains in Young Athletes” from the 2014 issue of AJSM.The authors performed a longitudinal cohort study of US military cadets and found that MCL injuries are relatively common in the athletic population. Male athletes are at significantly greater risk than females –of the 128 injuries in this study, 89% occurred in males. Intercollegiate athletes are also at greater risk than athlete...
2023-12-0428 min
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...
2023-11-251h 03
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...
2023-11-251h 03
PeerView Clinical Pharmacology CME/CNE/CPE VideoNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...
2023-11-251h 03
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...
2023-11-251h 03
PeerView Internal Medicine CME/CNE/CPE Video PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...
2023-11-251h 03
PeerView Internal Medicine CME/CNE/CPE Audio PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...
2023-11-251h 03PeerView Internal Medicine CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...
2023-07-291h 14PeerView Oncology & Hematology CME/CNE/CPE Video PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...
2023-07-291h 14PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...
2023-07-291h 14PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...
2023-07-291h 14PeerView Clinical Pharmacology CME/CNE/CPE VideoProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...
2023-07-291h 14PeerView Internal Medicine CME/CNE/CPE Video PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...
2023-07-291h 14
OncotargetDecoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein StabilityA new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.”
The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), encouraged the development of inhibitors that target other antiapoptotic proteins, particularly Myeloid Leukemia 1 (MCL-1). MCL-1 is among the top genes amplified in several cancers and is implicated in cancer progression, drug resistance and poor prognosis. It protects cancer cells from apoptosis and decreases their sensitivity to targeted agents or chemotherapeutics.
In this new editorial, researchers Shad...
2023-06-2802 minPeerView Clinical Pharmacology CME/CNE/CPE VideoDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL ManagementGo online to PeerView.com/YVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Across B-cell non-Hodgkin lymphoma settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell...
2023-01-141h 19
2022-12-0640 minRadio MCL Giovani RC ShowRadio MCL Giovani RC Diretta Studio 01/12/2022Puntata dedicata all'amore.Con Francesca e Chiara!
2022-12-0144 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 30/11/2022Seconda puntata dedicata alle canzoni italiane d'amore.Con Francesca e Chiara!
2022-11-3047 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Live Studio 28/11/2022Puntata dedicata all'amore con canzoni italiane.Insieme a Francesca e Chiara
2022-11-2844 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 25/11/2022Puntata dedicata alle donne!
2022-11-2543 min
Radio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 22/11/2022Anche oggi puntata ricca di canzoni richieste dai nostri ascoltatori!!!
2022-11-2245 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 17/11/2022Oggi una diretta sull'amicizia!!In studio Chiara e Francesca, con la regia del nostro Lele
2022-11-1744 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 15/11/2022Anche oggi una diretta ricca di musica, oggi in studio con: Francesca e Chiara, in cabina di regia, Lele!!
2022-11-1541 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 09/11/2022Eccoci alla seconda puntata della nostra emittente radiofonica!!!!
2022-11-0936 minRadio MCL Giovani RC ShowRADIO MCL GIOVANI - PUNTATA DI INAUGURAZIONEDa oggi è nata una nuova radio web!!!! RADIO MCL GIOVANI RC!!!
2022-11-0715 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...
2022-10-0559 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...
2022-10-0559 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...
2022-10-0559 minPeerView Internal Medicine CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...
2022-10-0559 minPeerView Clinical Pharmacology CME/CNE/CPE VideoDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...
2022-10-0559 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...
2022-10-0559 min
The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 min
Chimeric antigen receptor (CAR) t-cell therapy - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minEpisodes - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 min
Mantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minNon-Hodgkin lymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minChimeric antigen receptor (CAR) t-cell therapy - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minTreatment - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minEnglish - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minNon-Hodgkin lymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minLymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...
2022-05-2334 minEnglish - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minCoronavirus (COVID-19) - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minTreatment - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minNon-Hodgkin lymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minThe Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minLymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minEpisodes - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 minNon-Hodgkin lymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...
2022-05-1638 min
Le Voci del volontariatoIntervista a Margherita Peroni, Presidente Movimento Cristiano Lavoratori Unione territoriale di Brescia – Mantova (MCL)Margherita Peroni, Presidente Movimento Cristiano Lavoratori Unione territoriale di Brescia – Mantova (MCL) una realtà che quest’anno, a livello nazionale e provinciale, compie 50 anni.MCL è un ente di promozione sociale che si ispira alla dottrina sociale della Chiesa e si occupa di diversi servizi per i lavoratori e le famiglie.MCL offre servizi di CAF, patronato per i lavoratori ed è impegnato per la formazione, prima di tutto culturale, ma anche specifica per aiutare i lavoratori a comprendere i cambiamenti, il senso di quello che sta avvenendo con un’attenzione particolare al mondo dei giovani. I volontari sono da s...
2022-03-2207 min
This Must Be The Place: The Building Science PodcastBrad McLaughlin - MCL Construction Ltd.In this episode of This Must be The Place Shawna exchanges net-zero knowledge and industry best practices with Brad McLaughlin. He is the General Manager of the multi-award winning company MCL Construction Ltd. based in New Brunswick, Canada. MCL has been serving the greater Saint John area for over 40 years specializing in building custom homes and renovations.
In this episode:
• MCL was featured on CBC for building the first net zero home in the province. Yet, it sat on the market for longer than anticipated. Tune in to find out if it eventually sold and wh...
2022-01-2750 min
Cult Of OddEpisode 57: An MCL Xmas EveThis is 1 of 2 last episodes of The Odd Podd, catch #interviewroulette with Mark Christopher Lawrence! We've got terrifying Christmas traditions from around the world and Interesting facts about Christmas you might not know. MCL is best known for his series regular role as Big Mike on the NBC TV series CHUCK. He recently completed production on the hit ADULT SWIM TV show BLACK JESUS and is recurring on The PureFlix Show Malibu Dan The Family Man. He can be seen on the Disney Channel’s original TV movie Life Is Ruff and guest appearances on Lab Rats, Good Luck Char...
2021-12-261h 07
Cult Of OddEpisode 57: An MCL Xmas EveThis is 1 of 2 last episodes of The Odd Podd, catch #interviewroulette with Mark Christopher Lawrence! We've got terrifying Christmas traditions from around the world and Interesting facts about Christmas you might not know. MCL is best known for his series regular role as Big Mike on the NBC TV series CHUCK. He recently completed production on the hit ADULT SWIM TV show BLACK JESUS and is recurring on The PureFlix Show Malibu Dan The Family Man. He can be seen on the Disney Channel’s original TV movie Life Is Ruff and guest appearances on Lab Rats, Good Luck Char...
2021-12-261h 07
hodpodcastWhat You Should (and Shouldn't) Do After ACL and MCL Tears and SurgeryRegardless of whether you harmed your knee on the inclines, in the exercise center, on the field or from a slip and fall, returning to 100% after knee medical procedure can feel like a daunting task.
As a rule, that is on the grounds that it is.
Restoring from ACL or MCL medical procedure is a long cycle – and that interaction starts the second you conscious from sedation.
Upper leg tendon versus MCL Tears and Surgery
Upper leg tendon (foremost cruciate tendon) tears and MCL (average security tendon) tears are the two mo...
2021-05-2802 min
Blood & CancerHow I treat CLL and MCL: From ‘watch and wait’ to BCL2 and BTK inhibitors, CAR T-cell therapy, and transplantTreatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) have advanced in recent years, with more new developments on the horizon. James Gerson, MD, of the University of Pennsylvania, Philadelphia, reviewed some of these advances and future directions while describing how he would treat three patients. Host David H. Henry, MD, posed the following cases for consideration. Case 1 In a 75-year-old male with no comorbid illness, routine blood work revealed a WBC count of 15,000/mcL. The manual differential showed mature lymphocytes and smudge cells. The patient has no constitutional symptoms, but...
2021-03-1122 minThe New Grad Physio PodcastMCL Knee Injury Rehab - From The Bed To The FieldMCL (medial collateral ligament)injuries are very common but there are a lot of misconceptions about how to rehab these injuries.
When do you start?
Can you do exercises in the brace?
What exercises do you do?
How do you know when your athlete is ready to start running?
How do you know when they are ready to rejoin full training or do contact work?
If you want to know the answers to any or all of these questions then you are in the right place!
2021-02-2525 min
Rodinné podnikanieŠtruktúra a výhody rodinného holdinguKaždé rodinné podnikanie prechádza svojimi vývojovými štádiami. Na začiatku je to predovšetkým o vyhľadávaní a využívaní príležitostí, neskôr podnikanie rastie a pomaly dozrieva a prichádza čas poupratovať, konsolidovať a stabilizovať. Vhodným nástrojom konsolidácie rodinného podnikania a majetku je rodinný holding. V ďalšej časti podcastu Rodinné podnikanie sa Michal Šubín z Family office spoločnosti RSM CZ&SK a Matej Firický, partner advokátskej kancelárie MCL spoločne podelia s praktickými skúsenosťami týkajúcimi sa motivácie a cieľov spojených s konsolidáciou...
2020-12-2949 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minEnglish - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minThe Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minNon-Hodgkin lymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minNon-Hodgkin lymphoma - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minEpisodes - The Bloodline with Blood Cancer United PodcastMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...
2020-07-1343 min
Cambridge Masters Degree in Corporate Law (MCL) MOVEDPostgraduate Open Day MCL Presentation: Professor Brian CheffinsOn 1 November 2019 the University of Cambridge held its most recent Postgraduate Open Day (https://www.graduate.study.cam.ac.uk/events/postgraduate-open-day). As part of this hugely popular event, Professor Brian Cheffins, Director of the MCL, gave a talk that provided an overview of the MCL programme, MCL entry requirements and the application process. The presentation provided only a succinct overview of relevant points.
Key additional details are available on the full MCL website at:
https://www.mcl.law.cam.ac.uk/postgraduate-open-day
2019-11-1117 min
Cambridge Masters Degree in Corporate Law (MCL) MOVEDMCL Subject Forum 2019: (M2d) Corporate TaxationA student subject forum presentation given by Peter Harris who will lead a module on Corporate Taxation on the MCL in 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0817 minCambridge Masters Degree in Corporate Law (MCL) MOVEDMCL Subject Forum 2019: (M2b) Shareholder LitigationA student subject forum presentation given by Leslie Kosmin who will lead a module on Shareholder Litigation on the MCL in 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0819 minCambridge Masters Degree in Corporate Law (MCL) MOVEDMCL Subject Forum 2019: (M2e) International Merger ControlA student subject forum presentation given by Gavin Robert who will lead a module on International Merger Control on the MCL in 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0818 minCambridge Masters Degree in Corporate Law (MCL) MOVEDWelcome to MCL students 2019: Professor Mark ElliottA student subject forum presentation given by Chair of the Faculty Mark Elliott at the MCL subject forum on 8 October 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0811 minCambridge Masters Degree in Corporate Law (MCL) MOVEDIntroduction to the MCL subject forum 2019: Professor Brian CheffinsA student subject forum presentation given by Director of the MCL Professor Brian Cheffins at the MCL subject forum on 8 October 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0822 minCambridge Masters Degree in Corporate Law (MCL) MOVEDMCL Subject Forum 2019: (M2g) The Law Firm as a BusinessA student subject forum presentation given by Mark Smith who will lead a module on The Law Firm as a Business on the MCL in 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0813 minCambridge Masters Degree in Corporate Law (MCL) MOVEDMCL Subject Forum 2019: (M2c) Comparative Corporate GovernanceA student subject forum presentation given by Brian Cheffins who will lead a module on Comparative Corporate Governance on the MCL in 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0815 minCambridge Masters Degree in Corporate Law (MCL) MOVEDMCL Subject Forum 2019: (M2f) US Corporate LawA student subject forum presentation given by Laura Bradford who will lead a module on US Corporate Law on the MCL in 2019.
For more information about the MCL and the subjects available for study, please refer to the MCL website: http://www.mcl.law.cam.ac.uk
2019-10-0815 min